Empowering Communities: A Recap of Recent Initiatives by the Brazilian Huntington Association (ABH)

The Brazilian Huntington Association (ABH – Associação Brasil Huntington) is incredibly active and has been conducting numerous initiatives for the community. This level of commitment is vital because it not only benefits those affected by the disease but also raises the much-needed awareness about Huntington’s Disease. This article serves as قراءة المزيد……

Ashley Clarke, HD Advocate, shares her experience in uniQure headquarters

As well as being an ambassador for the Huntington’s Disease Youth Organisation (HDYO) Ashley Clarke is an advocate for the HD-Community Advisory Board (HD-CAB), a group that represents the patient voice in the design and conduct of clinical trials.   Following an HD-CAB advisory board meeting with uniQure in 2022 Ashley قراءة المزيد……

Rise Against Huntington’s: how two young high school students raised $2000 for Huntington’s Disease

Jasmine and Sai are high school students from the US.  They’re two young people who are determined to make a difference and inspire others to follow suit.  A fundraising initiative they set up and managed recently raised an incredible $2000 for Huntington’s Disease.  While initially planning to put value into قراءة المزيد……

Dimitri Poffé (Explore for Huntington) has his adventure shown in a new documentary

The HD Community already knows Dimitri Poffé’s adventures too well, and now, the world will too. The French traveler who is doing a bicycle trip through all South America to raise awareness for Huntington’s Disease will now have his own documentary to report his jorney. An epic 18.000-kilometer (11.200 mi) قراءة المزيد……

PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington’s Disease Patients

June 21, 2023 PDF Version – Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks –– Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes –  – Conference call and webcast to be held June 21st at 8:00 am EDT –  SOUTH PLAINFIELD, N.J., June 21, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared قراءة المزيد……

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~ ~ Neurofilament Light Chain (NfL) in cerebrospinal fluid (CSF) was below baseline at 24 months in قراءة المزيد……

arArabic